FDA public Meeting Statement on Abuse Deterrent Opioid Formulations

FDA public Meeting Statement on Abuse Deterrent Opioid Formulations 10-30-14

GHLF Idaho Board of Pharmacy Proposed Rule Testimony 10-22-14

GHLF Idaho Board of Pharmacy Testimony 8-6-14

GHLF Indiana Health Finance Commission Biosimilars Testimony

GHLF Pennsylvania House Biosimilars Testimony